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Abstract 
A number of prognostic factors have been reported in non-small cell lung 
cancer (NSCLC). Although lymph node metastasis is the most poorly 
predictive value in completely resected NSCLC, a significant number of 
patients have a fatal recurrence even in node-negative curative NSCLC. 
Recently inflammatory response has been shown as a predictive value in 
NSCLC. Neutrophils and lymphocytes play an important role in cancer 
immune response. In this study, we retrospectively examined the impact of 
preoperative peripheral neutrophil and lymphocyte counts on survival, and 
investigated the relationships of these factors to clinicopathological factors 
in node-negative NSCLC. A total 237 patients were evaluated. When the 
cut-off value of neutrophil count was 4500 mm-3 with a maximum log-rank 
statistical value, overall 5-year survival rates were 79.7% for the 
low-neutrophil-count group and 69.5% for the high-neutrophil-count group 
(P = 0.04). When the cut-off value of lymphocyte count was 1900 mm-3 
with a maximum log-rank statistical value, overall survival rates were 
67.9% for the low-lymphocyte group and 87.7% for the high-lymphocyte 
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group (P < 0.001). High-neutrophil-counts were associated with tumor size 
(P = 0.002) and pleural invasion (P < 0.001). Low-lymphocyte-counts were 
correlated with vascular invasion (P = 0.018) and recurrence of NSCLC (P 
= 0.01). Multivariate analysis showed that the lymphocyte count was an 
independent prognostic factor (hazard ratio: 3.842; 95% confidence interval: 
1.827 – 8.078; P < 0.001), but the neutrophil count was not (P = 0.185). We 
conclude that a peripheral lymphocyte count, which is associated with 
vascular invasion, is an independent prognostic factor in node-negative 
NCSLC. 
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Introduction 
Non-small cell lung cancer (NSCLC) is one of the most common causes 
of cancer-related death. A number of prognostic factors have been proposed 
for patients with NSCLC, such as age, sex, performance status, tumor size, 
pleural invasion, lymphatic invasion, vascular invasion, lymph node 
metastasis, and distant metastasis [1-4]. Although lymph node metastasis is 
recognized as the worst prognostic factor in completely resected NSCLC [2, 
3], a significant number of patients have systemic recurrence even in 
node-negative curative NSCLC. Recently, the systemic inflammatory 
response has also been shown to have predictive value [5-7]. The 
neutrophil-lymphocyte ratio has been found to be an important indicator of 
adverse prognosis in colorectal cancer [8, 9], gastric cancer [10, 11], and 
NSCLC [12, 13]. In addition, neutrophils have been implicated in the 
promotion of aerogenous metastasis in patients with bronchioalveolar 
carcinoma [14], and lymphocytes recognized as playing a fundamental role 
in cell-mediated immunologic destruction of host cancer cells [15]. The 
purpose of the present study, therefore, was to examine the impact of 
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preoperative peripheral neutrophil and lymphocyte counts on survival and to 
investigate the relationships of the neutrophil and lymphocyte counts to 
clinicopathological factors in node-negative NSCLC. 
 
Materials and methods 
Patients 
We conducted a retrospective analysis of patients diagnosed with NSCLC 
who underwent surgery at the Tsukuba University Hospital between January 
2000 and December 2009. Data from 455 patients were obtained from the 
hospital’s database. Two hundred eighteen patients were excluded owing to 
positive lymph node metastasis (n = 94), unmeasured differential leukocyte 
count (n = 59), incomplete radical surgery (n = 42), preoperative treatment 
(n = 18), suspicion of granulocyte-colony stimulating factor-producing 
tumor with leukocytosis (n = 3), and autoimmune disease (n = 2). Thus, 237 
patients were included in this study. No patients had infection, such as 
pneumonia. A peripheral venous blood sample was collected from each 
patient within a month before surgery. A Blood test was performed using 
6 
 
fully automated blood cell counting system and confirmed by laboratory 
technicians. Histological classification was carried out according to the 
WHO guidelines [16]. The tumors were staged according to the TNM 
classification of malignant tumors [17]. Vascular invasion was detected by 
using elastica van Gieson staining and lymphatic invasion was determined 
using D2-40 staining.  
Statistical analysis 
Univariate analysis was performed using the Kaplan-Meier method, and 
statistical significances between survival curves were assessed by the 
log-rank test. Overall survival was determined from the date of surgery to 
the date of death or last follow-up. In selecting the optimal cutoff value for 
determining the effect of the neutrophil and lymphocyte count on overall 
survival, a running log-rank test was performed at intervals of 100 mm-3 
between the 5th percentile and the 95th percentile of neutrophil and 
lymphocyte counts. The cutoff value was defined when the log-rank 
statistical value was maximum [18]. To examine the association with 
clinicopathological factors, the chi-square test (or Fisher’s exact test when 
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appropriate) was used for categorical variables, and the t test for continuous 
variables. To assess the independent predictive value of survival of different 
variables, multivariate analysis was performed using the Cox proportional 
hazards model. The result was considered to be significant when the P value 
was less than 0.05. Statistical analyses were performed using PASW 
Statistics 18 (SPSS, Chicago, IL, USA). 
 
Results 
Patients’ characteristics 
The clinicopathological characteristics of the patients are shown in Table 
1. There were 147 men and 89 women. The patients’ age at the time of 
operation ranged from 29 to 89 years (mean age, 66.9 years). The mean 
follow-up was 43 months (range, 1-118 months). Thirteen patients were 
performed postoperative adjuvant chemotherapy and 29 patients had 
recurrences of lung cancer. The overall 5-year survival rate of all 237 
patients was 77.7%. 
Optimal cutoff values for neutrophil and lymphocyte counts 
8 
 
As for the neutrophil count, the maximum log-rank statistical value was 
4.210 (P = 0.04) when the cutoff value was 4500 mm-3. Kaplan-Meier 
survival curves according to the optimal cutoff value are shown in Figure 
1A. The overall 5-year survival rates were 79.7% for the 
low-neutrophil-count group (neutrophil count ≤ 4500 mm -3; n = 191) and 
69.5% for the high-neutrophil-count group (neutrophil count > 4500 mm-3; n 
= 46). As for the lymphocyte count, the maximum log-rank statistical value 
was 13.19 (P < 0.001) when the cutoff value was 1900 mm-3. Kaplan-Meier 
survival curves according to the optimal cutoff value are shown in Figure 
1B. The overall 5-year survival rates were 67.9% for the 
low-lymphocyte-count group (lymphocyte count ≤ 1900 mm-3; n = 110) and 
87.7% for the high-lymphocyte-count group (lymphocyte count > 1900 
mm-3; n = 127). 
Relationships between preoperative neutrophil and lymphocyte counts and 
clinicopathological factors 
The relationships between the neutrophil and lymphocyte counts and 
clinicopathological factors are shown in Table 2 and 3. The high neutrophil 
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count was significantly associated with tumor size (P = 0.002) and pleural 
invasion (P < 0.001), which influenced tumor status and staging. The high 
neutrophil count was also significantly correlated with C-reactive protein (P 
< 0.001). On the other hand, the low lymphocyte count was significantly 
correlated with vascular invasion (P = 0.018) and recurrence of NSCLC (P 
= 0.01). As for age, sex, performance status, smoking index, comorbidity 
and past history, surgical procedure, histological type, albumin, and cause of 
death, no significant differences were detected between the groups. 
Multivariate analysis 
The results are shown in Table 4. The lymphocyte count was an 
independent prognostic factor for overall survival (hazard ratio: 3.842; 95% 
confidence interval: 1.827 – 8.078; P < 0.001). Other independent 
prognostic factor was tumor size (hazard ratio: 3.568; 95% confidence 
interval: 1.748 – 7.282; P < 0.001). The neutrophil count, albumin, 
C-reactive protein, pleural invasion, vascular invasion, and lymphatic 
invasion were predictive values only in univariate analysis, but not in 
multivariate analysis. 
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Discussion 
The results of this study suggest that a high peripheral lymphocyte count 
is an independent positive prognostic factor in node-negative NSCLC. 
Previously, the lymphocyte count, an inexpensive, reproducible, and widely 
available blood test, was found to have an independent prognostic 
significance in pancreatic [19, 20] and breast cancers [21]. In NSCLC, 
Hespanhol et al reported that the lymphocyte count might be a valuable 
contribution to prognosis estimation in stage IIIB or IV patients [22], and 
Muers et al proposed a lymphocyte count as one of the predictive models in 
patients who had not received curative treatment [23]. To the best of our 
knowledge, this is the first report of the prognostic significance of 
lymphocyte counts in early-stage NSCLC with curative treatment, and with 
additional investigation of the relationships with clinicopathological factors. 
Lymphocytes play a fundamental role in cell-mediated immunologic 
destruction of various cancers [15, 24, 25]. An increased number of 
tumor-infiltrating lymphocytes (TILs) is correlated with a favorable 
prognosis in cancer [26]. Cluster-of-differentiation (CD) 8+ T cells have a 
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pivotal role in tumor growth control by cytotoxic T-cell killing and 
apoptosis [27, 28], and CD4+ T cells play a central role in orchestrating the 
immune response to cancers [29]. In NSCLC, the role of TILs is still 
controversial. Some reports showed that TILs correlated with improved 
prognosis [28-33], while others reached the opposite conclusion [34]. In our 
study, the peripheral low lymphocyte count was significantly associated 
with vascular invasion. Al-Shibli et al showed that a low level of stromal 
CD8+ lymphocyte infiltration was associated with an increased incidence of 
angiolymphatic invasion [31], and Ruffini et al showed that TILs were more 
frequent in tumors with microscopic vascular invasion [32]. The 
pathogenesis is unclear, but there might be a relationship between 
lymphocytes and vascular invasion, which is one of the important 
prognostic factors in NSCLC [1, 35]. In our study, the fact that the low 
lymphocyte count had a significant correlation with vascular invasion would 
support this relationship. 
 In the present study, only the univariate analysis showed that a high 
neutrophil count was a poor prognostic factor in node-negative NSCLC. An 
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increasing neutrophil count has been identified as an independent prognostic 
factor in patients with advanced NSCLC [4, 13]. The difference between 
those previous reports and the present study is tumor stage. Sarraf et al also 
did not find any association between the absolute value of the neutrophil 
count on survival after complete resection of early-stage NSCLC [12]. In 
this study, the high neutrophil count was significantly associated with tumor 
size and pleural invasion. Therefore, a high neutrophil count may indicate 
only the severity or nature of inflammation occurring within or around the 
tumor. Neutrophil-Lymphocyte ratio was previously reported as a prognostic 
factor in NSCLC [12, 13]. In our study, Neutrophil-Lymphocyte ratio was a 
significant prognostic factors in univariate analysis, but not in multivariate 
analysis in preliminary study (data not shown), probably because 
Neutrophil-Lymphocyte ratio was a direct confounding factor of 
lymphocyte count. 
C-reactive protein and albumin have also been shown to be independent 
prognostic factors in NSCLC [5-7, 22, 23, 36]. In the present study, the 
C-reactive protein and albumin were significant prognostic factors in 
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univariate analysis, but not in multivariate analysis. The C-reactive protein 
was associated with the neutrophil count. Therefore it is considered that the 
C-reactive protein may reflect an inflammatory response to the tumor as 
well as the neutrophil count. Hypoalbuminemia is reported to associate with 
inflammation and malnutrition especially in advanced cancer [5, 37]. 
However, in the present study, albumin correlated with neither neutrophil 
count nor lymphocyte count, and few patients were malnourished.  
We investigated patients with node-negative NSCLC. We considered that 
the analysis could be difficult in node-positive NSCLC because patients 
with node-positive NSCLC were performed various postoperative treatment. 
In fact, the neutrophil or lymphocyte count had no impact on survival in 
node-positive NSCLC (data was not shown). In the present study, 20 out of 
43 patients (47%) died from non-NSCLC. Therefore we also analyzed the 
impact of prognosis using disease specific survival and disease free survival 
as endpoint. The results showed that lymphocyte count was still a significant 
prognostic factor and neutrophil count was not significant by univariate 
analysis (data was not shown).  
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In conclusion, the results of this study indicate that a preoperative 
peripheral lymphocyte count is an independent prognostic factor in 
node-negative NSCLC. The subject for future investigation is to determine 
the mechanism of association between lymphocytes and prognosis by 
clarifying the relationships among peripheral lymphocyte counts, TILs, and 
vascular invasions. 
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A short descriptive title of Figure 1A 
Figure 1A. Overall survival curves at the optimal cutoff value of the 
neutrophil counts (4500 mm-3)  
 
Legends of Figure 1A. 
The overall 5-year survival rates were 79.7% for the low-neutrophil-count 
group (neutrophil count ≤ 4500 mm -3; n = 191), which was significantly 
higher than 69.5% for the high-neutrophil-count group (neutrophil count > 
4500 mm-3; n = 46). 
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A short descriptive title of Figure 1B. 
Figure 1B. Overall survival curves at the optimal cutoff value of the 
lymphocyte counts (1900 mm-3)  
 
Legends of Figure 1B 
The overall 5-year survival rates were 67.9% for the low-lymphocyte-count 
group (lymphocyte count ≤ 1900 mm -3; n = 110), which was significantly 
lower than 87.7% for the high-lymphocyte-count group (lymphocyte count 
> 1900 mm-3; n = 127). 
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A short descriptive title of Table 1. 
Table 1. Clinicopathological characteristics of patients 
 
Legends of Table 1 
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; Lob, 
lobectomy or bilobectomy; Seg, segmentectomy; Wedge, wedge resection; 
Ad, adenocarcinoma; Sq, squamous cell carcinoma; Large, large cell 
carcinoma. 
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A short descriptive title of Table 2 
Table 2. Relationship between preoperative peripheral neutrophil counts and 
clinicopathological factors 
 
Legends of Table 2 
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; 
COPD, chronic obstructive pulmonary disease; Lob, lobectomy or 
bilobectomy; Seg, segmentectomy; Wedge, wedge resection; Ad, 
adenocarcinoma; Sq, squamous cell carcinoma; Large, large cell carcinoma. 
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A short descriptive title of Table 3. 
Table 3. Relationship between preoperative peripheral lymphocyte counts 
and clinicopathological factors 
 
 
Legends of Table 3 
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; 
COPD, chronic obstructive pulmonary disease; Lob, lobectomy or 
bilobectomy; Seg, segmentectomy; Wedge, wedge resection; Ad, 
adenocarcinoma; Sq, squamous cell carcinoma; Large, large cell carcinoma.  
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A short descriptive title of Table 4. 
Table 4. Univariate and multivariate analyses of prognostic factors in 
node-negative NSCLC. 
 
 
Legends of Table 4 
CI, Confidence interval. 
 
Figure 1A
Figure 1B
Total
n = 237
Age (mean ± SD), years 66.9 ± 10.1
Sex (male / female) 147 / 89
ECOG performance status (0 / 1 / 2) 173 / 15 / 1
Smoking index (mean ± SD) 733 ± 776
Resected side (right / left) 137 / 100
Surgical procedure
(Pneumonectomy / Lob / Seg / Wedge)
Histological type (Ad / Sq / Large / others) 159 / 53 / 12 / 13
Pathological staging (I / II / III) 204 / 32 / 1
Tumor status (T1 / T2 / T3 / T4) 136 / 80 / 20 / 1
Tumor size (mean ± SD), mm 26.8 ± 17.2
Pleural invasion (positive / negative) 59 / 178
Vascular invasion (positive / negative) 78 / 157
Lymphatic invasion (positive / negative) 58 / 177
Leukocyte counts (mean ± SD), mm-3 6300 ± 1800
Neutrophil counts (mean ± SD), mm-3 3700 ± 1400
Lymphocyte counts (mean ± SD), mm-3 1900　±　710
Albumin (mean ± SD), g/dL 4.0　± 0.4
C-reactive protein (mean ± SD), mg/dL 0.45 ± 1.63
Postoperative adjuvant Chemotherapy 13
Recurrences of NSCLC 29
Cause of death
 (lung cancer / others / unknown)
Table 1. Clinicopathological characteristics of patients
1 / 189 / 24 / 23
21 / 20 / 2
SD, standard deviation; ECOG, Eastern Cooperative 
Oncology Group; Lob, lobectomy or bilobectomy; Seg, 
segmentectomy; Wedge, wedge resection; Ad, 
adenocarcinoma; Sq, squamous cell carcinoma; Large, 
≤ 4500 mm-3 > 4500 mm-3
n = 191 n = 46
Age (mean ± SD), years 66.5 ± 9.8 67.1 ± 10.3 0.722
Sex (male / female) 114 / 76 33 / 13 0.140
ECOG performance status (0 / 1 / 2) 144 / 12 / 1 30 / 3 / 0 0.867
Smoking index (mean ± SD) 692 ± 788 908 ± 702 0.089
Comorbidity and past history
  COPD 8 5 0.083
  Interstitial pneumonia 5 3 0.187
  Old pulmonary tuberculosis 10 2 0.578
  Asthma 10 1 0.334
  Hypertension 72 15 0.52
  Diabetes mellitus 21 4 0.443
  Hyperlipidemia 26 5 0.62
  Ischemic heart disease 13 2 0.414
  Arrhythmia 15 3 0.524
Surgical procedure
(Pneumonectomy / Lob / Seg / Wedge)
Histological type
(Ad / Sq / Large / others)
Pathological staging (I / II / III) 169 / 21 / 1 35 / 11 / 0 0.064
Tumor status (T1 / T2 / T3 / T4) 119 / 60 / 11 /
1
17 / 20 / 9 / 0 0.002
Tumor size (mean ± SD), mm 25.1 ± 15.2 33.9 ± 22.8 0.002
Pleural invasion (positive / negative) 38 / 153 21 / 25 <0.001
Vascular invasion (positive / negative) 58 / 132 20 / 25 0.075
Lymphatic invasion (positive / negative) 45 / 145 13 / 32 0.467
Leukocyte counts (mean ± SD), mm-3 5600 ± 1200 8900 ± 1600 <0.001
Lymphocyte counts (mean ± SD), mm-3 1800 ± 700 2100 ± 800 0.026
Albumin (mean ± SD), g/dL 4.0 ± 0.4 4.0 ± 0.4 0.697
C-reactive protein (mean ± SD), mg/dL 0.22 ± 0.42 1.44 ± 3.48 <0.001
Postoperative adjuvant Chemotherapy 11 2 0.521
Recurrences of NSCLC 23 6 0.852
Cause of death
(lung cancer / others / unknown)
132 / 39 / 8 /
12
27 / 14 / 4 / 1 0.180
15 / 14 / 1 6 / 6 / 1 0.819
Table 2. Relationship between preoperative peripheral neutrophil counts and
clinocopathological factors
Neutrophil Counts
P  value
0 / 151 / 20 /
20
1 / 38 / 4 / 3 0.178
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; COPD, 
chronic obstructive pulmonary disease; Lob, lobectomy or bilobectomy; Seg, 
segmentectomy; Wedge, wedge resection; Ad, adenocarcinoma; Sq, squamous 
cell carcinoma; Large, large cell carcinoma. 
≤ 1900 mm-3 > 1900 mm-3
n = 127 n = 110
Age (mean ± SD), years 68.1 ± 10.1 66.5 ± 10.1 0.063
Sex (male / female) 75 / 51 72 / 38 0.348
ECOG performance status (0 / 1 / 2) 92 / 10 / 1 82 / 5 / 0 0.385
Smoking index (mean ± SD) 659 ± 761 820 ± 787 0.110
Comorbidity and past history
    COPD 4 9 0.090
    Interstitial pneumonia 6 2 0.192
    Old pulmonary tuberculosis 6 6 0.798
    Asthma 8 3 0.192
    Hypertension 48 39 0.709
    Diabetes mellitus 9 16 0.062
    Hyperlipidemia 12 19 0.075
    Ischemic heart disease 9 6 0.607
    Arrhythmia 10 8 0.862
Surgical procedure
(Pneumonectomy / Lob / Seg / Wedge)
Histological type
(Ad / Sq / Large / others)
Pathological staging (I / II / III) 105 / 22 / 0 99/ 10 / 1 0.106
Tumor status (T1 / T2 / T3 / T4) 65 / 51 / 11 / 0 71 / 29 / 9 /1 0.097
Tumor size (mean ± SD), mm 28.6 ± 16.8 24.9 ± 17.6 0.098
Pleural invasion (positive / negative) 36 / 91 23 / 87 0.402
Vascular invasion (positive / negative) 50 / 75 28 / 82 0.018
Lymphatic invasion (positive / negative) 35 / 90 23 / 87 0.208
Leukocyte counts (mean ± SD), mm-3 5600 ± 1500 7100 ± 1800 <0.001
Neutrophil counts (mean ± SD), mm-3 3500 ± 1300 3800 ± 1600 0.080
Albumin (mean ± SD), g/dL 4.0 ± 0.4 4.0 ± 0.3 0.307
C-reactive protein (mean ± SD), mg/dL 0.46 ± 1.92 0.44 ± 1.22 0.905
Postoperative adjuvant Chemotherapy 7 6 0.985
Recurrences of NSCLC 22 7 0.010
Cause of death
(lung cancer / others / unknown)
77 / 33 / 7 / 10 82 / 20 / 5 / 3 0.100
17 / 14 / 1 4 / 6 / 1 0.521
Table 3. Relationship between preoperative peripheral lymphocyte counts and
clinocopathological factors
Lymphocyte Counts
P  value
0 / 101 / 12 /
14
1 / 88 / 12 / 9 0.621
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; COPD, 
chronic obstructive pulmonary disease; Lob, lobectomy or bilobectomy; Seg, 
segmentectomy; Wedge, wedge resection; Ad, adenocarcinoma; Sq, squamous 
5-year
survival rate
P -
value P -value
Neutrophil counts > 4500 mm-3 46 69.5 0.040 1.64 (0.789 - 3.405) 0.185
≤ 4500 mm-3 191 79.7 1
Lymphocyte counts ≤ 1900 mm-3 127 67.9 < 0.001 3.84 (1.827 - 8.078) < 0.001
> 1900 mm-3 110 87.7 1
Albumin ≤ 3.5 g/dL 27 59.7 0.020 1.04 (0.455 - 2.398) 0.918
> 3.5 g/dL 210 80.3 1
C-reactive protein > 0.1 mg/dL 101 68.5 0.009 1.84 (0.951 - 3.573) 0.070
≤ 0.1 mg/dL 130 84.9 1
Tumor size > 3.0 cm 71 57.4 < 0.001 3.57 (1.748 - 7.282) < 0.001
≤ 3.0 cm 166 87.4 1
Pleural invasion positive 59 67.3 0.014 1.010 (0.504 - 2.021) 0.979
negative 178 81.1 1
Vascular invasion positive 78 65.2 < 0.001 1.559 (0.788 - 3.085) 0.202
negative 157 83.4 1
Lymphatic invasion positive 58 63.2 0.004 1.763 (0.933 - 3.333) 0.081
negative 177 82.6 1
Table 4. Univariate and multivariate analyses of prognositic factors in node-negative NSCLC.
Variable
Multivariate analysis
Adjusted hazard ratio
(95% CI)
CI, Confidence interval
Univariate analysis
ｎ
